跳至主要内容
临床试验/NCT01877590
NCT01877590已完成4 期

Alpha-lipoic Acid Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease

Wuhan General Hospital of Guangzhou Military Command1 个研究点 分布在 1 个国家目标入组 66 人开始时间: 2013年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
66
试验地点
1
主要终点
Alpha-lipoic acid regress the left ventricular mass

研究概览

简要总结

Cardiovascular complications account for the highest mortality in type 2 diabetic patients, mainly due to coronary artery disease (CAD). Most of the attention in treating CAD in type 2 diabetes is understandably directed toward treating coronary artery conditions. However there are other treatable culprits in these patients.

Left ventricular hypertrophy (LVH) is widespread in type 2 diabetic patients with CAD, even in the absence of hypertension. It is a strong predictor of cardiovascular events and all-cause mortality. Regression of LVH has been associated with an improved prognosis, independent of change in blood pressure (BP). Therefore, cardiovascular events and mortality in type 2 diabetes with CAD might will be reduced if the investigators can find novel therapies to regress LVH.

Alpha-lipoic acid reduces oxidative stress which then regresses LVH. Alpha-lipoic acid can improve endothelial function in diabetic conditions. Hence, the main aim of this study was to assess whether alpha-lipoic acid could regress LVM in type 2 diabetic patients with CAD.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Investigator)

入排标准

年龄范围
40 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Type 2 diabetes
  • Left ventricular hypertrophy
  • HbA1c below 7.0%
  • blood pressure <130/80 mmHg

排除标准

  • Patients were excluded if they were currently alpha-lipoic acid for one year, had a previous adverse reaction to alpha-lipoic acid.
  • hey were also excluded if they had renal and liver dysfunction, heart failure, or malignancy, or were unable to give informed consent.
  • Patients with contraindications to cardiac magnetic resonance (CMR) (pacemakers, claustrophobia) were also excluded, as were pregnant or lactating women.

研究组 & 干预措施

alpha-lipoic acid group

Experimental

alpha-lipoic acid 600 mg daily for one year.

干预措施: alpha-lipoic acid (Drug)

结局指标

主要结局

Alpha-lipoic acid regress the left ventricular mass

时间窗: one year

Alpha-lipoic acid 600 mg daily for one year.

次要结局

  • The change of endothelial dysfunction before and after alpha-lipoic acid intervention.(one year)

研究者

发起方
Wuhan General Hospital of Guangzhou Military Command
申办方类型
Other
责任方
Principal Investigator
主要研究者

Xiang Guang-da

Director of Endocrinol Dept.

Wuhan General Hospital of Guangzhou Military Command

研究点 (1)

Loading locations...

相似试验

Alpha-lipoic Acid Reduces Left Ventricular Mass in... | 临床试验